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Abstract
Objective: Previous research has shown that a better therapeutic relationship (TR) predicts more positive attitudes towards
antipsychotic medication, but did not address whether it is also linked with actual adherence. This study investigated
whether the TR is associated with adherence to antipsychotics in patients with schizophrenia.
Methods: 134 clinicians and 507 of their patients with schizophrenia or a related psychotic disorder participated in a
European multi-centre study. A logistic regression model examined how the TR as rated by patients and by clinicians is
associated with medication adherence, adjusting for clinician clustering and symptom severity.
Results: Patient and clinician ratings of the TR were weakly inter-correlated (rs=0.13, p=0.004), but each was independently
linked with better adherence. After adjusting for patient rated TR and symptom severity, each unit increase in clinician rated
TR was associated with an increase of the odds ratio of good compliance by 65.9% (95% CI: 34.6% to 104.5%). After
adjusting for clinician rated TR and symptom severity, for each unit increase in patient rated TR the odds ratio of good
compliance was increased by 20.8% (95% CI: 4.4% to 39.8%).
Conclusions: A better TR is associated with better adherence to medication among patients with schizophrenia. Patients’
and clinicians’ perspectives of the TR are both important, but may reflect distinct aspects.
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Introduction
Adherence to treatment in schizophrenia is generally regarded
as central for optimizing recovery [1]. However, non-adherence
remains a significant clinical problem, with rates of non-adherence
approximately 50% [2]. Non-adherence is linked to relapse,
rehospitalisation and poor quality of life. Meanwhile, the
therapeutic relationship (TR) between patient and clinician has
been found to be important for treatment adherence in other
psychiatric conditions. The TR has been extensively studied since
it was highlighted by Freud [3]. He wrote that ‘‘The first aim of
the treatment consists in attaching [the patient] to the treatment
and the person of the physician’’. Since then, the TR has been
described as the ‘‘quintessential integrative variable’’ across
different forms of psychotherapy [4] and has been consistently
found to predict the outcome of therapy [5]. In psychiatric
treatment outside formal psychotherapy, the TR is a more global
concept [6]. It tends to be used to denote the quality of the whole
relationship rather than specific aspects such as the collaborative
bond or the transference relationship [6]. Nonetheless, there is
increasing evidence that the TR also predicts outcome of complex
psychiatric treatment across diagnoses and treatment settings [7–
14].
Previous research in psychiatry has investigated the predictive
role of the TR with respect to so-called distal outcomes of
treatment such as symptom change and social functioning. Few
studies have investigated whether the TR is associated with
proximal treatment outcomes, e.g., engagement and adherence.
This is of interest given the suggestion that a causal chain links
each outcome measure in a continuum to the next more distal
outcome measure [15], e.g. that adherence to medication leads to
better symptom levels, and is important for designing interventions
to influence specific outcomes in the treatment chain.
In a recent study by Day et al. [16], the TR was found to predict
attitudes towards antipsychotic medication. Various studies have
found that a more favourable TR is linked with better adherence
to medication in other psychiatric disorders, namely depression
[9,17] and bipolar disorder [18]. Moreover, Holzinger et al. [19]
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adherence as reported by patients themselves. It remains unclear
whether the TR also predicts adherence to medication when
adherence is not based on self-report. Since previous research has
shown that the clinician and patient perspective on the quality of
the TR are not the same in psychiatric treatments [20], both
perspectives need to be considered.
Aim of the study
The aim of this study was to investigate the association between
both clinician and patient ratings of the TR and adherence to
antipsychotic medication.
Methods
Data Collection
Data was collected in the baseline assessment of a randomized
controlled trial to evaluate a new intervention to structure patient-
clinician communication, DIALOG, described in detail elsewhere
[21]. Data were collected before patients began participating in
the trial so they were not influenced by the trial protocol. Data
were collected between December 2002 and May 2004.
Researchers not involved in the patients’ care conducted the
interviews. Patients were interviewed in the clinical setting or at
home according to their preference.
Setting
The setting was community mental health services in Granada
(Spain), Groningen (The Netherlands), London (United King-
dom), Lund (Sweden), Mannheim (Germany), and Zurich
(Switzerland) covering urban and mixed urban-rural areas. The
number of community mental health teams included per country
varied between 2 (Lund) and 6 (London). All teams were
multidisciplinary and provided comprehensive care programmes
for people with severe and enduring mental illness. They operated
a key worker system in which every patient has a designated
clinician, i.e. the keyworker, working within a team with lead
responsibility for care co-ordination and delivery [21].
Participants
Clinicians had a professional qualification in mental health or a
minimum of one-year professional experience in an outpatient
setting, and an active caseload as a key worker. The caseloads of
participating clinicians were screened to identify suitable patients
meeting the following inclusion criteria: living in the community
and treated as outpatients by community psychiatric teams; at
least 3 months of continuous care in the current service; capable of
giving informed consent; having sufficient knowledge of the
language of the host country; a primary diagnosis of schizophrenia
or related psychotic disorder (ICD-10=F20-F29); aged between
18 and 65 years of age; having routinely at least one meeting with
their clinician every two months; and having no severe organic
psychiatric illness or primary substance abuse. Patients were first
informed about the study by clinicians and, if they agreed,
approached by a researcher for consent.
Ethics statement
The study was approved by the following ethics committees:
Hospital Universitario San Cecilio Ethics Committee (Granada,
Spain), Certified Medical Ethical Committee of the University
Medical Centre (Groningen, The Netherlands), East London and
the City Health Authority Research Ethics Committee (London,
UK), The Research Ethics Committee, Medical Faculty, Lund
university (Lund, Sweden), Medizinische Ethik-Kommission II der
Ruprecht-Karls-Universita ¨t Heidelberg (Mannheim, Germany)
and Kantonale Ethikkommission (Zurich, Switzerland).
Measures
Diagnosis. Psychiatric diagnosis was obtained through a
standardized, computer based method using operationalised
criteria (OPCRIT) [22].
Therapeutic Relationship. The TR was assessed with the
Helping Alliance Scale, which has a patient (HAS-P) and a
clinician (HAS-C) version. Both scales have established reliability
and validity [23,24]. The patient version has 6 questions. Five
questions are self-rated on a scale from 0 (not at all) to 10 (entirely):
receiving the right treatment, feeling understood, feeling criticized,
keyworker committed to and actively involved in treatment, trust
in keyworker and his/her professional competence. The sixth
question ‘‘How do you feel immediately after a session with your
keyworker?’’ has three possible responses: worse, unchanged or
better, scored 0, 5 and 10 respectively. The six questions are
summed and divided by 6 to yield a mean score (a higher score
indicates a better relationship). The clinician version has five
questions, self-rated on a scale from 0 (not at all) to 10 (entirely):
get along with patient, understand the patient and his/her views,
look forward to meeting patient, actively involved in patient’s
treatment, can help the patient and treat him/her effectively. The
scores are summed and divided by 5 to yield a mean score (a
higher score indicates a better relationship).
Medication Adherence. Adherence with antipsychotic
medication over the previous three months was rated using the
Buchanan criteria [25] by the clinician in closest contact with the
patient. There were 3 possible ratings: 1=.75%; 2=25–75%; and
3=,25% (a higher score indicates poorer adherence). The rating
was based on knowledge of the patient from routine clinical contact.
In 78% of cases, collateral information was also used to make the
rating: in 49% of cases, this was information obtained from depot,
supervised drug intake or drug testing. In a further 29%, this was
information obtained from others involved in the patient’s care (e.g.
pharmacist, general practitioner, family member).
Symptoms. Interviewers assessed patients’ symptoms on the
30-item Positive and Negative Syndrome Scale (PANSS) [26].
Inter-rater-reliability using videotaped interviews for PANSS was
good (Cohen’s kappa=0.71). The scale assesses positive, negative
and general symptoms and is rated on a scale of 1–7 (with higher
scores indicating more severe symptoms).
Socio-demographic characteristics of patients and clinicians and the
time patients had spent in psychiatric treatment were also obtained.
Statistical Analysis
The association between length of time in treatment and the TR
was explored with bivariate correlations (Spearman rho). A one-
way ANOVA was used to compare professional background of
keyworkers on both keyworker and patient ratings of the TR. The
odds of good adherence to medication were compared to the odds
of poorer adherence using a logistic regression with standard
errors robust to clustering of patients within clinicians. The
independent predictors were patient and clinician ratings of the
TR and symptoms, as symptoms are known to influence
adherence in schizophrenia [27]. Country was also entered into
the model. The dependent variable was adherence to antipsy-
chotic medication. The number of patients for whom there was
complete data for this analysis was 466. An additional analysis was
conducted on the subgroup of patients receiving depot medication
as the reliability of assessing adherence in this subgroup is high,
i.e., the depot injection either happened or not. The same logistic
regression model was applied. This analysis was conducted on 90
Therapeutic Relationship and Medication Adherence
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Mac (2010) and Stata 9.2 (2007).
Results
Participants
134 clinicians consented to participate, a 74% consent rate.
From their caseloads, 507 patients agreed to participate, a 67%
consent rate. The number of patients per clinician ranged from 1
to 12, with a mean of 3.73 patients each. 88 patients were
recruited in Granada, 99 in Groningen, 99 in London, 61 in Lund,
83 in Mannheim and 77 in Zurich. Sociodemographic and clinical
characteristics of participants are presented in Table 1. The mean
number of years since patients’ first contact with mental health
services was 15.6 (SD 10.3).
Association between patient and clinician ratings of the
therapeutic relationship
Patient and clinician ratings were weakly correlated with each
other, rs=0.13 (p=0.004).
Length of time in treatment and the therapeutic
relationship
Length of time in treatment was not associated with patient
ratings (rs=20.12, p=0.79) or clinician ratings (rs=20.00,
p=0.88) of the TR.
Professional background of keyworkers and the
therapeutic relationship
There were no significant differences across different keyworker
professional backgrounds and patient (F=1.34, p=0.26) or
keyworker ratings (F=0.54, p=0.70) of the TR.
Therapeutic relationship and medication adherence
The distribution of adherence ratings was skewed (see Table 2)
so it was transformed into a categorical variable with two
categories: good adherence, i.e., $75% (N=367) or average/
poor adherence, i.e., ,75% (N=118).
In the average patient (see Table 3), for each unit increase in
clinician rated TR score, the odds ratio of good compliance was
increased by 65.9% (95% CI: 34.6% to 104.5%). A lesser increase
of 20.8% (95% CI: 4.4% to 39.8%) in the odds ratio for good
compliance was observed per unit increase in patient rated TR
score. There was a small negative association between symptoms
and adherence: OR=0.894 (95% CI: 0.971 to 0.996). As country
did not make a significant contribution to the model, it was
excluded in the final model (Wald test x5
2=5.86, p=0.32).
Among the patients receiving depot medication, 22% had poor
adherence and 78% had good adherence. In this depot subgroup
(see Table 4), for each unit increase in clinician rated relationship
score, the odds ratio of good compliance was statistically
significantly increased by 50.9% (95% CI: 1.01 to 2.25). For each
unit increase in patient rated relationship score, the odds ratio of
good compliance was increased by 34.8% (95% CI: 0.95 to 1.90)
which was significant at p=0.09.
To give some indication of the clinical relevance, the adherence
of patients with better and poorer keyworker ratings of the TR was
compared descriptively. This was done using 7 as a cutoff point as
in previous studies [23]: above 7 on a satisfaction based measure
indicates a better relationship while below 7 indicates a poorer
relationship. If keyworkers rated the relationship with their
patients less highly (,7 on the HAS), 42% of their patients had
poor adherence compared to 17% if keyworkers rated the
relationship more highly ($7 on the HAS).
Discussion
There are two main findings from this study. Firstly, the TR is
associated with adherence to, not just attitudes towards,
antipsychotic medication in the treatment of schizophrenia.
Secondly, although only weakly correlated with each other, both
patient and clinician perspectives of the TR are independently
associated with adherence. In the depot subgroup, where the
assessment of adherence is more objective and hence more
reliable, the clinician’s perspective remained significantly associ-
ated with adherence whereas the patient’s perspective was
significant at the 10% level.
With over 450 patients, this is the largest study to date to
investigate the association between the TR in the treatment of
schizophrenia and adherence to antipsychotic medication. It used
Table 1. Sociodemographic & Clinical Characteristics of
Clinicians and Patients.
Clinician Characteristics N=134
Age: mean (SD) 43.81 (8.73)
Gender (%) Female 62.6
Male 37.4
Profession (%)
Psychiatric nurse 48.1
Social worker 22.2
Psychiatrist 10.4
Psychologist 5.2
Other 14.1
Length of service in years: mean (SD) 15.4 (22.0)
Total caseload: mean (SD) 30.7 (59.7)
Therapeutic relationship HAS-Clinician: mean
(SD) [range]
7.5 (1.3) [0–10]
Patient Characteristics N=507
Age: mean (SD) 42.2 (11.4)
Gender (%) Female 34
Male 66
Time in treatment in years: mean (SD) 15.6 (10.3)
Previous hospital admissions: mean (SD) 5.2 (7.3)
Symptoms: PANSS Positive 14.9 (5.8)
Symptoms: PANSS Negative 16.5 (6.6)
Symptoms: PANSS General 32.3 (9.6)
Therapeutic relationship HAS-Patient: mean
(SD) [range]
8.0 (1.7) [0–10]
doi:10.1371/journal.pone.0036080.t001
Table 2. Distribution of Adherence Ratings.
Adherence to antipsychotic medication Percentage
Good (.75%) 75.7%
Average (25–75%) 20.2%
Poor (,25%) 4.1%
doi:10.1371/journal.pone.0036080.t002
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settings across six European countries. The associations between
the TR and adherence were seen after adjusting for symptom
levels and possible clustering effects of patients treated by the same
clinician and were not influenced by country. A limitation is that
adherence was, in some cases, assessed by the clinician [29] who
also rated their relationship with the patient. It should be
considered that a clinician’s ratings of the TR and medication
adherence may not be independent of each other, i.e., their TR
ratings are influenced by their estimations of medication
adherence and their estimations of adherence may be influenced
by the relationship they have with the patient. However, the
assessment of adherence was based on collateral information from
depot, supervised drug intake, drug tests and other clinicians
(psychiatrist, general practitioner, pharmacist) and informal carers
in the majority of cases. Moreover, the association between TR
and adherence held true in a sub-sample of patients on depot
medication where the assessment of adherence is objective and
independent of any potential rater bias.
The sample is not necessarily representative for all patients with
schizophrenia in community mental health care. Most patients
had been in treatment for many years and were, on the whole, well
engaged in treatment. Those who agreed to participate in the
study, both patients and clinicians, may have had better TRs.
Thus, there may have been a selection bias, including fewer
patients with shorter treatment histories and poorer TRs.
However, the TR ratings reported by patients (mean 8.0) in the
current study are similar to those reported in other studies, e.g. a
mean of 8.1 in outpatients with schizophrenia [34]. Moreover,
length of time in treatment was not associated with the quality of
the TR from either patient or clinician perspective. Finally, the
associations are cross-sectional so causal relationships may not be
inferred.
Patient and clinician ratings of the TR were only weakly
correlated with each other, which in other studies has also been
found in relation to needs for care [28]. It may be seen as
intriguing that, despite the fact that patient and clinician
perspectives on the TR are only weakly inter-correlated, both
are independently associated with adherence. Hence, each
perspective must be capturing some distinctive aspects. The
patient’s rating may be tapping into a subjective assessment of the
social and personal experience of the relationship with their
clinician. If they get along well with their clinician, they may be
more willing to follow the clinician’s advice on treatment.
Clinicians have different views of the TR with a given patient.
They may compare it to relationships with other patients and
consider how the patient is functioning more generally. In turn,
how well a patient is functioning may coincide, to some degree,
with adherence to treatment.
In the current study, the clinician’s perspective had a somewhat
stronger association with adherence than the patient’s perspective.
This is in contrast to psychotherapy, where the patient’s
perspective appears to be most strongly related to outcome [30].
It is, however, consistent with other findings in psychiatry, which
have measured both the patient’s and clinician’s perspectives.
These studies suggest that the clinician’s perspective may be more
strongly related to outcome in complex psychiatric treatment of
depression [17] and schizophrenia, psychosis or major affective
disorder [7,31]. It may be the case that clinicians rate the TR
higher when patients adhere to their recommendations, i.e., they
view their relationship with these patients more positively because
they are more adherent. On a speculative note, this may also be
related to the degree to which treatment is oriented to the needs of
the patient as identified by themselves, which is stronger in
psychotherapy, versus the needs of the patient as identified by the
service, which is stronger in psychiatric treatment of patients with
severe mental illness.
As mentioned above, the findings do not imply causality and
could be interpreted in different ways. A better TR may lead to
better adherence or better adherence may lead to a better TR or
both. Future prospective studies with first episode samples would
help to disentangle the direction of the effect. The associations
might also be explained by other factors. One possibility is that
those patients who form better relationships with their clinicians
do so because they can and will also do better on a range of
outcomes, in this case, more likely to adhere to medication. This
might be an index of their individual potential rather than
anything to do with the potential of the relationship per se to
influence treatment outcomes. Bentall et al. [32] examined
whether the TR indirectly mediates or has a direct causal
influence on outcome in a large trial of cognitive behaviour
therapy for psychosis. They found that the relationship had a
direct causal influence on outcome, which was not explained by
other factors influencing patients’ potential to form a good TR.
Future studies might explore how to achieve better TRs. Little is
known about what makes good relationships and how they might
be improved, with a few intervention studies showing promising
results [21,33]. In the light of the current findings, studies
developing and testing interventions that focus on collaboration in
relationships and specifically on talk about medication may be
indicated.
Conclusion
In conclusion, the current findings suggest that better TRs
between patients with schizophrenia and their clinicians in
community care are important for adherence to antipsychotic
medication. Furthermore, patient and keyworker perspectives on
Table 3. Associations between Therapeutic Relationship and
Adherence to Antipsychotic Medication in a logistic
regression model based on 466 patients.
Adherence to Antipsychotics
Adjusted
odds ratio 95% CI p
Patient rating of relationship 1.21 1.04 to 1.40 p=0.017
Keyworker rating of relationship 1.66 1.35 to 2.05 p,0.001
Symptoms 0.98 0.97 to 0.99 p=0.014
doi:10.1371/journal.pone.0036080.t003
Table 4. Associations between Therapeutic Relationship and
Adherence to Antipsychotic Medication in depot subgroup in
a logistic regression model based on 90 patients.
Adherence to Antipsychotics
Adjusted
odds ratio 95% CI p
Patient rating of relationship 1.35 0.95 to 1.90 p=0.090
Keyworker rating of relationship 1.51 1.01 to 2.25 p=0.042
Symptoms 0.98 0.95 to 1.01 p=0.279
doi:10.1371/journal.pone.0036080.t004
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